← Back to Clinical Trials
Recruiting NCT07402109
NCT07402109 CBCT Guided Markerless SBRT for Renal Cell Cancer
◆ AI Clinical Summary
Plain-language summary for patients
| NCT ID | NCT07402109 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Erasmus Medical Center |
| Condition | Renal Cell Carcinoma (RCC) |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2026-04-01 |
| Primary Completion | 2030-01-01 |
Trial Parameters
Condition Renal Cell Carcinoma (RCC)
Sponsor Erasmus Medical Center
Study Type INTERVENTIONAL
Phase N/A
Enrollment 40
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2026-04-01
Completion 2030-01-01
Interventions
Additional radiation due to imaging
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This study aims to improve the treatment of kidney tumors using radiotherapy, by investigating whether kidney cancer can be more effectively irradiated with the help of new imaging techniques
Eligibility Criteria
Inclusion Criteria: * Patients with histologically proven non-metastastic RCC or high suspicion of RCC based on imaging without histological evidence * No metastatic lesions * Patients must be 18 years or older * Ability to understand the requirements of the study and to give written informed consent, as determined by the treating physician. Written informed consent Exclusion Criteria: * Previous high-dose radiotherapy in the region of the kidney
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology